Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05874674 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

Study acronym: Nafamostat
StatusRecruiting
PhaseNot applicable
Started2023-12-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 30, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2024-07-28
Enrolling by Invitation→Recruiting Study Status, Contacts/Locations v2
Trial statusEnrolling by Invitation→Recruiting
Primary completion date2023-12-31→2025-12-31
Completion date2024-12-31→2026-12-31
Study sitesdetails revised at 1 of 1 site
2023-08-17
Recruiting→Enrolling by Invitation Study Status, Contacts/Locations v1
Trial statusRecruiting→Enrolling by Invitation
Study sitesdetails revised at 1 of 1 site
2023-05-22
Original filing
Comparison nafamostat and low molecular weight heparin among dialysis patients
Trial Details
NCT Number NCT05874674
Lead Sponsor Wonju Severance Christian Hospital
Conditions Dialysis; Complications, Bleeding
Enrollment 100 participants
Start Date 2023-12-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-30